September 7, 2009
Drug yields positive response in people with skin, brain cancer
The Hedgehog signaling pathway is involved in a preliminary study and case report describing positive responses to an experimental anticancer drug in a majority of people with advanced or metastatic basal cell skin cancers. One patient with the most common type of pediatric brain cancer, medulloblastoma, also showed tumor shrinkage.
Initial results of the drug trial, conducted at Johns Hopkins in Baltimore, Wayne State University’s Karmanos Cancer Center in Detroit and the Translational Genomics Research Institute in Scottsdale, Ariz., are published online Sept. 3 in the New England Journal of Medicine. The publication also details side effects of the drug, including muscle cramping, hair loss, fatigue and low blood sodium.
The compound, known as GDC-0449, is designed to inhibit the Hedgehog signaling pathway, thought to fuel growth of some cancers. The pathway was named for the oblong hedgehoglike shape of fly embryos when a key gene in the pathway is disrupted.
Related research by Johns Hopkins and Genentech investigators reported online in the Sept. 3 issue of Science Express reveals more findings on the medulloblastoma case.
“We know that both of these cancer types have mutations in Hedgehog pathway genes, and our results with Hedgehog inhibitors could be the starting point for developing a new type of therapy for these intractable cancers,” said Charles Rudin, associate director for Clinical Research at the Johns Hopkins Kimmel Cancer Center.
In the Phase I clinical study, 33 patients with advanced basal cell skin cancer were treated with GDC-0449, an oral drug made by Genentech. Of the 33, 18 had metastatic disease spread to other organs, and 15 had locally advanced disease at the original tumor site. Half the patients with metastatic cancer responded to the therapy as measured by tumor regression of 30 percent or more. Nine of the 15 patients with local recurrences also responded to the drug. The remaining patients had either stable or progressive disease at a median of nearly 10 months follow-up. Analysis of patients’ skin biopsies revealed that the drug inhibited the Hedgehog signaling pathway.
Rudin and his team also gave the drug to one patient with advanced medulloblastoma, as described in a separate case report in NEJM. The patient, whose cancer recurred 18 months after initial surgery and treatment, had tried several additional therapies with no success. Investigators found that samples of his tumor had very high levels of activity in the Hedgehog pathway.
“Within a few weeks of the treatment, the drug had a remarkable effect on the patient,” Rudin said. “He went from being nearly bedridden with significant pain to exercising and having no pain.” Rudin recounted that the patient’s tumor began to regress, he gained weight, and his requirements for blood transfusion improved. Two months later, however, the cancer progressed and drug treatment could not be sustained. He subsequently died.
Additional research, published online in the Sept. 3 issue of Science Express by investigators at Johns Hopkins and Genentech, focuses on how the medulloblastoma tumor became resistant to the Hedgehog inhibitor. When the cancer recurred, it had acquired a mutation in a gene known as SMO, which encodes the target of the Hedgehog inhibitor drug. This mutation prevents GDC-0449 from binding to its target. In a mouse model of medulloblastoma selected for GDC-0449 resistance, the researchers found a mutation in the very same location in the mouse SMO gene.
Research over the past several years has shown that mutations in genes encoding a family of proteins known as tyrosine kinases are important causes of relapse in cancer patients treated with other targeted cancer therapies, including lung cancer patients treated with erlotinib. Mutations in SMO, like the one found in this patient, may similarly be an important cause of resistance to Hedgehog inhibitors, Rudin said. Researchers are now evaluating strategies for treating cancers with acquired resistance, to try to maintain the initial good responses seen in some patients treated with these drugs.
The Hedgehog gene got its name from scientists who first studied it in fruit flies. In humans, the Hedgehog pathway has long been known to contain genes that control fetal development and cell growth, and, when altered, the pathway can cause excessive cell growth, a hallmark of cancer.
Investigators have begun a clinical trial of GDC-0449 at several U.S. cancer centers for children with medulloblastoma. The disease is typically treated with surgery, radiation and chemotherapy, which can have severe side effects. When it recurs, the cancer is often fatal.
Basal cell skin cancer is the most common type of cancer in adults and is often cured with surgery. In a very small percentage of people, it spreads in the body. There are no chemotherapy drugs proven effective in treating metastatic basal cell cancer.
In addition to Rudin, the NEJM study investigators are Christine Hann, John Laterra, Barbara Coleman and Julie Brahmer, all of Johns Hopkins; Daniel Von Hoff, R. Tibes, G. Weiss, M. Borad, of the Translational Genomics Research Institute; Patricia LoRusso, of the Karmanos Cancer Institute; and Robert Yauch, Christopher Callahan, Ling Fu, Thomas Holcomb, J. Reddy, H. Mackey, B. Lum, W. Darbonne, J. Marsters, Jeremy Stinson, Stephen Gould, Frederic de Sauvage and Jennifer Low, of Genentech.
Von Hoff, LoRusso and Rudin have received research funding from Genentech. Rudin is a grant awardee from Genentech. LoRusso has received lecture fees for speaking at the invitation of Genentech. Brahmer and Laterra have received consulting fees from Genentech. De Sauvage has received patents in the field of Hedgehog signaling. GDC-0449 is based on technology licensed from The Johns Hopkins University, and the university is entitled to a percentage of income from the sale of related products.
The Science study researchers are, from Genentech, Robert L. Yauch, Gerrit J. P. Dijkgraaf, Bruno Alicke, Thomas Januario, Christina P. Ahn, Thomas Holcomb, Kanan Pujara, Jeremy Stinson, Christopher A. Callahan, Tracy Tang, J. Fernando Bazan, Zhengyan Kan, Somasekar Seshagiri, Stephen E. Gould, Jennifer Low and Frederic J. de Sauvage; and, from Johns Hopkins, Rudin and Christine Hann.
Rudin received research funding for a GDC-0449 phase I trial and a BioOncology Grant Program Award from Genentech.